aibioVRAX Virax Biolabs Group Ltd
Virax Biolabs Group (VRAX) news
Virax Biolabs Group Ltd is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VRAX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Virax Biolabs Group news
We have not published a story on Virax Biolabs Group yet. When there is news, it will appear here.
What Virax Biolabs Group does
Virax Biolabs Group Limited is a Cayman Islands holding company that conducts its operations through subsidiaries in the United Kingdom, the United States and China. It describes itself as a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases. Its current strategic focus is post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. Its lead development program, ViraxImmune, is a T cell-based immune profiling and diagnostic platform whose initial clinical focus is Long COVID, myalgic encephalomyelitis / chronic fatigue syndrome and post-treatment Lyme disease. The filing says ViraxImmune has not been cleared, approved or authorized for diagnostic use in any jurisdiction, and that the company completed a pre-submission meeting with the FDA in calendar year 2025 to inform its regulatory planning. Its second platform, ImmuneSelect, is a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents. The company previously distributed third-party test kits under the ViraxClear and ViraxVet brands, but says these lines are no longer active strategic product lines. Virax Biolabs commenced operations in 2013 and completed its Nasdaq IPO in July 2022 under the symbol VRAX.
| Product or program | What it is | Stage |
|---|---|---|
| ViraxImmune | T cell-based immune profiling and diagnostic platform for PAIS and related conditions | in development; pre-submission meeting with FDA held in 2025 |
| ImmuneSelect | Research-use-only peptide pools, ELISpot plates and immune reagents | research use only |
Virax Biolabs Group annual financials
| Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 |
|---|---|---|
| Revenue | $6,331 | $156,419 |
| Research and development | $1.8 million | $1.6 million |
| Net income (loss) | -$6.1 million | -$6.7 million |
| Cash from operations | -$4.6 million | -$6.2 million |
| Cash and equivalents | $4.2 million | $3.6 million |
Questions about Virax Biolabs Group
What is the ticker symbol of Virax Biolabs Group?
Virax Biolabs Group Ltd trades under the ticker VRAX on NASDAQ.
Where is Virax Biolabs Group listed?
Virax Biolabs Group Ltd is listed on NASDAQ.
Which country or territory is Virax Biolabs Group listed under?
Our directory records Virax Biolabs Group Ltd under United States.
Does aibio.space cover Virax Biolabs Group?
aibio.space lists Virax Biolabs Group Ltd among 2,820 public biotech companies and publishes its news here as stories appear.
What does Virax Biolabs Group develop?
Virax Biolabs Group Limited is a Cayman Islands holding company that conducts its operations through subsidiaries in the United Kingdom, the United States and China. It describes itself as a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases.
What is ViraxImmune from Virax Biolabs Group?
ViraxImmune: T cell-based immune profiling and diagnostic platform for PAIS and related conditions Stage: in development; pre-submission meeting with FDA held in 2025.
What is ImmuneSelect from Virax Biolabs Group?
ImmuneSelect: Research-use-only peptide pools, ELISpot plates and immune reagents Stage: research use only.
What was Virax Biolabs Group's revenue last year?
$6,331 for the fiscal year ended Mar 31, 2025, as reported to the SEC.
Is Virax Biolabs Group profitable?
Virax Biolabs Group Ltd reported a net loss of $6.1 million for the fiscal year ended Mar 31, 2025, and used $4.6 million of cash in operations, per its annual report to the SEC.
How much does Virax Biolabs Group spend on research and development?
$1.8 million in the fiscal year ended Mar 31, 2025, per its annual report.
How much cash does Virax Biolabs Group have?
$4.2 million in cash at Mar 31, 2025, per its 20-F.
Investor discussion: Virax Biolabs Group
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
Listing details
- Company
- Virax Biolabs Group Ltd
- Ticker
- VRAX
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction